Health News Today, Nov 14: Prostate, Plaque, Medicare
In health news today, leading oncology specialists issued the first direct prostate cancer screening recommendations in sixteen years while a landmark cardiovascular trial revealed dual-drug therapy can shrink existing heart artery plaque by over twenty percent. At the federal level, regulators announced urgent nationwide recalls for an allergen-tainted bone supplement and an insulin pump software glitch, alongside an extended Medicare freeze on new hospice and home health agencies to protect seniors from fraud. Here is what these developments mean for adults aged 45 to 75 navigating preventive care, heart health, and medical device safety this weekend.
Cancer Society Urges Routine Prostate Screening for Men Over 50
The American Cancer Society has updated its prostate cancer screening guidelines to directly recommend routine screening every two years starting at age 50 for average-risk men, according to guidance published in CA: A Cancer Journal for Clinicians and reported November 12 by CNN Health. For Black men and individuals with a strong family history, the society recommends starting annual screening at age 45. Moving away from passive discussion models, the update reflects long-term trial evidence showing that regular prostate-specific antigen (PSA) blood tests substantially reduce disease-related mortality. The guideline defines abnormal PSA levels as 3.0 ng/mL or higher for men aged 69 and younger, and 6.5 ng/mL or higher for men aged 70 to 74, after which testing shifts back to individualized shared decision-making. Oncologists noted that establishing a baseline PSA reading in your 40s or 50s offers valuable predictive insight into long-term risk.
What it means for you: If you are a man aged 45 to 70 who has never had a PSA test, ask your primary care doctor whether establishing a baseline screening fits your personal history. For adults over 70, continue reviewing ongoing screening choices with your physician.
Dual Cholesterol Therapy Shrinks Heart Artery Plaque by 21%
Combining two cholesterol-lowering medications can shrink coronary artery plaque more effectively than high-dose statins alone, according to a randomized trial in JAMA Cardiology covered November 13 by Medical News Today. The 18-month trial tracked 104 adults with stable coronary artery disease and over 50% arterial narrowing. Participants receiving intensive combination therapy—rosuvastatin (40 mg) plus the intestinal cholesterol absorption inhibitor ezetimibe (10 mg) daily—experienced a 21.1% reduction in coronary plaque volume, compared with a 13.6% reduction in patients taking high-dose atorvastatin (40 mg) alone. Dual therapy lowered low-density lipoprotein (LDL) cholesterol by 65% (falling from 127.4 mg/dL to 42.5 mg/dL), compared to 38% on atorvastatin. Notably, 90% of dual-therapy patients showed plaque regression, with pronounced reductions in rupture-prone noncalcified plaque, pairing well with everyday choices for how to maintain cardiovascular health naturally.
What it means for you: If you have known heart disease or arterial plaque, ask your cardiologist or primary physician whether combination lipid-lowering therapy fits your risk profile, and never modify prescription therapies on your own. Promptly report any muscle pain or unusual fatigue to your doctor.
FDA Alerts Consumers to Recall of OsteoDenx Bone Supplements
The U.S. Food and Drug Administration posted a nationwide voluntary recall for two lots of OsteoDenx® dietary supplement capsules manufactured by bioQuad Life Sciences after routine federal inspections found undeclared milk, according to an FDA Safety Alert issued November 13. The bone-support supplement contains lactoferrin derived from cow's milk, which was omitted from the ingredient label, creating serious or life-threatening anaphylactic risks for individuals with milk allergies. The recall covers 30-capsule (UPC 8 57294 00722 8) and 60-capsule cartons (UPC 8 57294 00734 1) under LOT#0524100 (exp. 05/2027) and LOT#0625041 (exp. 08/2028), distributed nationwide from November 2024 through November 11, 2026, via Amazon, bioquad.com, resellers, and a California clinic. While no illnesses have been reported, shipments remain halted until updated packaging is ready.
What it means for you: If you or a family member has a dairy allergy, check your supplement cabinet immediately and discard or return affected OsteoDenx cartons for a refund. Those without dairy allergies face no health hazard, but anyone noticing allergic symptoms should seek medical evaluation right away.
Tandem Recalls Insulin Pump App Over Missing Bolus Glitch
Federal regulators posted a Class 2 device recall for the Tandem Mobi Insulin Pump mobile application for Android due to a software flaw that can silently cancel mealtime boluses, according to the FDA Medical Device Recalls Database updated November 12. Affecting Android app versions 3.5.4, 3.5.2.2, and 3.5.2.1 used by over 4,000 patients nationwide, the glitch occurs when an entered blood glucose level matches the user's active target glucose value: the immediate ("Now") portion of an Extended Bolus is erroneously reduced to zero units without any on-screen alert. Because total insulin delivered falls below prescribed amounts, users face an unrecognized risk of severe hyperglycemia. Manufacturer Tandem Diabetes Care advises customers to avoid using Extended Bolus on Android devices and rely solely on Standard Boluses until a software patch is deployed.
What it means for you: If you or an older relative uses a Tandem Mobi insulin pump with an Android phone, refrain from using the Extended Bolus feature and use Standard Boluses instead. Consult your endocrinologist or diabetes educator if you observe unexplained high blood glucose levels.
Medicare Extends Six-Month Freeze on Home Health and Hospices
The Centers for Medicare & Medicaid Services extended its temporary nationwide freeze on new hospice and home health agency enrollments for six months through May 12, 2027, according to a CMS Press Release published November 12. Originally imposed in May 2026, the moratoria prevent fraudulent operators from entering Medicare while federal investigators deploy enhanced analytics to combat widespread billing scams. In October, a targeted enforcement action in California revoked 145 hospice and home health providers associated with over $703 million in improper payments. The policy modification allows established, compliant agencies in good standing to open branch locations, ensuring that legitimate palliative and home care services remain uninterrupted during Medicare's Fall Open Enrollment Period.
What it means for you: During open enrollment through December 7, protect your coverage by never sharing your Medicare number with unsolicited marketers offering 'free' home services or hospice enrollment. Review Medicare summary notices carefully with family members and consult your doctor or State Health Insurance Assistance Program (SHIP) before signing with new agencies.
Related reading: daily health news updates and FDA recalls.
Sources
CNN Health: American Cancer Society Updates Prostate Cancer Screening Guidelines
Medical News Today: Combining Two Cholesterol Drugs Shrinks Artery Plaque More Effectively
FDA Safety Alert: bioQuad Life Sciences Issues Recall of OsteoDenx Dietary Supplement
FDA Medical Device Recalls: Tandem Mobi Insulin Pump Android Application Correction
This roundup is for general information only and is not medical advice.
